Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$305.98M net income for the year ended September 30, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| October 1, 2024 – September 30, 2025 | $3,371,468,000 | November 21, 2025 | 10-K ↗ |
| October 1, 2023 – September 30, 2024 | $2,884,358,000 | November 21, 2025 | 10-K ↗ |
| October 1, 2022 – September 30, 2023 | $2,377,227,000 | November 21, 2025 | 10-K ↗ |
| October 1, 2021 – September 30, 2022 | $2,166,808,000 | November 22, 2024 | 10-K ↗ |
| October 1, 2020 – September 30, 2021 | $1,536,493,000 | December 7, 2023 | 10-K ↗ |
| October 1, 2019 – September 30, 2020 | $1,190,856,000 | December 6, 2022 | 10-K ↗ |
| October 1, 2018 – September 30, 2019 | $1,076,996,000 | December 3, 2021 | 10-K ↗ |
| October 1, 2017 – September 30, 2018 | $876,828,000 | December 7, 2020 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:Revenues · Retrieved October 12, 2026
Response SHA-256: 6519f676e62bc2f1a26dae4731e67d2fc07d4d6e79a62ae370c98575bf89d1c2
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.